Statera Biopharma, Inc. announced advancement of its next-gen research activities that builds upon the immune modulation activity of STAT-200 on Toll-Like Receptors (TLRs) to improve drug characteristics and clinical benefit beyond opioid receptors. The research is based on the discovery that STAT-200, which originally was designed to antagonize opioid receptors, modulates multiple signaling pathways through receptors known as TLRs. These receptors act as master controllers of inflammation.

Statera's discovery platform identifies novel compositions that build upon STAT-200 by modulating multiple cellular targets, versus one, to restore cellular homeostasis. These findings have led to the selection of promising new compositions with the potential to treat a range of inflammatory-related diseases. The platform rapidly screened billions of potential compositions, resulting in hundreds of promising targets.

The top ten compositions were highly compelling, and three of them are currently being synthesized for biologic validation. Statera partnered with MolSoft, a leader in computational chemistry and bioinformatics software, to conduct the computational discovery through its proprietary Rapid Isostere Discovery Engine (RIDE) technology.